Study of Biomarkers in Tissue Samples From Patients With Breast Cancer
NCT ID: NCT01004796
Last Updated: 2016-02-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
OBSERVATIONAL
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This research study is looking at tissue samples from patients with breast cancer.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Identification of Biomarkers in Women at High Risk or Average Risk of Breast Cancer
NCT00897416
Biomarkers for Breast Cancer Risk in African American Women
NCT01736306
Study of Breast Tissue in Women Not Previously Diagnosed With Breast Cancer Who Are Undergoing Fine Needle Aspiration
NCT00896636
Establishment of Normal Breast Epithelial Cell Lines From Patients at High Risk for Breast Cancer
NCT00001496
Studying Urine and Blood Samples in Women With Newly Diagnosed Breast Cancer
NCT00766454
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Identify by mass spectroscopy and site-specific mutagenesis the post-translational modifications of estrogen-related receptor alpha (ERRα1) that are responsible for ERRα1 function as a constitutive activator rather than a down-modulator of transcription of estrogen response element-regulated genes in tumors of patients with breast cancer.
* Produce a panel of monoclonal antibodies to ERRα1 by standard hybridoma methods that can be used to distinguish between the activator and repressor forms of this receptor in these patients.
* Validate the utility for immunohistochemistry (IHC) assays of some of the ERRα-specific sera by performing IHC and quantitative real-time PCR on some primary breast carcinomas.
* Correlate the results of IHC studies on archival paraffin sections of primary breast tumors using monoclonal antibodies to ERRα1, ERRα1 status, currently assayed biomarkers, and course of treatment with patient outcomes.
OUTLINE: Breast tumor tissue samples are obtained from a tissue bank in the form of frozen tumors and paraffin-embedded sections on microarray blocks. Monoclonal antibodies (MOABs) to ERRα1 are produced using antigens in these tissue samples and immunohistochemical studies are performed using the MOABs. Cytogenetic studies are performed on DNA purified from these tissue samples.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
cytogenetic analysis
microarray analysis
mutation analysis
immunohistochemistry staining method
immunologic technique
mass spectrometry
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of breast cancer
* Tumor tissue available
* The following clinical information must be known:
* ErbB2 status
* Nodal status
* Percent S phase
* Hormone receptor status:
* Estrogen receptor and progesterone receptor status known
PATIENT CHARACTERISTICS:
* Menopausal status not specified
PRIOR CONCURRENT THERAPY:
* Not specified
120 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
University of Wisconsin, Madison
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Janet E. Mertz, PhD
Role: STUDY_CHAIR
University of Wisconsin, Madison
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
WCCC-CO-TEMP
Identifier Type: -
Identifier Source: secondary_id
CDR0000357299
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.